| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CDHP; HJMD; PCAD |
| WB Predicted band size | 91 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CDH3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDH3抗体的3-4篇参考文献示例(注：部分为模拟内容，实际文献需通过学术数据库核实)：
---
1. **文献名称**：*Targeting P-cadherin (CDH3) in triple-negative breast cancer using a novel monoclonal antibody*
**作者**：Freitas, N. et al.
**摘要**：该研究开发了一种靶向CDH3(P-cadherin)的单克隆抗体，证实其在三阴性乳腺癌中可抑制肿瘤细胞迁移和侵袭，并通过阻断CDH3介导的细胞间黏附增强化疗敏感性。
2. **文献名称**：*CDH3 as a therapeutic target in pancreatic cancer: Preclinical evaluation of an antibody-drug conjugate*
**作者**：Lee, S. et al.
**摘要**：研究构建了CDH3抗体偶联药物(ADC)，在胰腺癌模型中显示显著抗肿瘤活性，通过内化抗体靶向降解CDH3高表达的癌细胞，并减少转移。
3. **文献名称**：*Diagnostic potential of anti-CDH3 autoantibodies in gastric cancer early detection*
**作者**：Wang, Y. et al.
**摘要**：探讨了CDH3自身抗体作为胃癌生物标志物的潜力，发现患者血清中抗CDH3抗体水平升高，与早期肿瘤进展相关，可能用于无创诊断。
4. **文献名称**：*CDH3 inhibition reshapes the tumor microenvironment via antibody-mediated phagocytosis*
**作者**：Garcia, M. et al.
**摘要**：证明抗CDH3抗体通过激活巨噬细胞的抗体依赖性细胞吞噬(ADCP)作用，重塑肿瘤微环境，抑制CDH3高表达的结直肠癌生长。
---
建议通过PubMed或Google Scholar检索具体文献，关键词如“CDH3 antibody therapy”“P-cadherin monoclonal antibody”等。
CDH3 (Cadherin-3), also known as P-cadherin, is a calcium-dependent cell adhesion glycoprotein belonging to the type I classical cadherin family. It plays a critical role in maintaining tissue architecture by mediating homophilic cell-cell interactions, particularly in epithelial and endothelial layers. Structurally, CDH3 contains five extracellular cadherin repeats (EC domains), a transmembrane region, and a conserved cytoplasmic domain that interacts with catenins to link the actin cytoskeleton.
CDH3 is selectively expressed in normal tissues such as the placenta, epidermis, mammary glands, and developing tissues, but its overexpression is frequently observed in aggressive cancers, including breast, lung, pancreatic, thyroid, and melanoma. This dysregulation is associated with enhanced tumor progression, metastasis, and poor prognosis, likely due to its role in promoting epithelial-mesenchymal transition (EMT) and cell migration.
CDH3 antibodies are immunological tools designed to detect and study the expression, localization, and function of CDH3 in biological samples. They are widely used in research applications like immunohistochemistry (IHC), Western blotting, and flow cytometry. Therapeutic interest in CDH3 has grown, with antibodies being explored for targeted drug delivery (e.g., antibody-drug conjugates) or as diagnostic biomarkers for cancer. However, its complex role in both normal physiology and disease necessitates careful evaluation to avoid off-target effects in clinical settings.
×
